Psoriasis in those planning a family, pregnant or breast‐feeding. The Australasian Psoriasis Collaboration
- 23 May 2017
- journal article
- review article
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 59 (2) , 86-100
Abstract
The Australasian Psoriasis Collaboration has reviewed the evidence for managing moderate to severe psoriasis in those who are pregnant or are breast‐feeding, or planning a family. The severity of the psoriasis, associated comorbidities and specific anti‐psoriasis treatment, along with other exposures, can have a deleterious effect on pregnancy outcomes. Psoriasis itself increases the risk of preterm and low birthweight babies, along with spontaneous and induced abortions, but no specific birth defects have been otherwise demonstrated. The baseline risk for a live born baby to have a major birth defect is 3%, and significant neuro‐developmental problem is 5%. In Australia, pregnant women with psoriasis are more likely to be overweight or obese, depressed, or smoke in their first trimester, and are also less likely to take prenatal vitamins or supplements. Preconception counselling to improve maternal, pregnancy and baby health is therefore strongly encouraged. The topical and systemic therapies commonly used in psoriasis are each discussed separately, with regards to pregnancy exposure, breast‐feeding and effects on male fertility and mutagenicity. The systemic therapies included are acitretin, adalimumab, apremilast, certolizumab, ciclosporin, etanercept, infliximab, ixekizumab, methotrexate, NBUVB, prednisone, PUVA, secukinumab and ustekinumab. The topical therapies include dithranol (anthralin), calcipotriol, coal tar, corticosteroids (weak, potent and super‐potent), moisturisers, salicylic acid, tacrolimus, and tazarotene. As a general recommendation, effective drugs that have been widely used for years are preferable to newer alternatives with less foetal safety data. It is equally important to evaluate the risks of not treating, as severe untreated disease may negatively impact both mother and the foetus.Keywords
This publication has 75 references indexed in Scilit:
- Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2013
- Unintended pregnancy in the United States: incidence and disparities, 2006Contraception, 2011
- Psoriasis and pregnancy outcomes: A nationwide population-based studyJournal of the American Academy of Dermatology, 2011
- Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeedingRheumatology, 2010
- Pregnancy outcomes in psoriasis: Why do we know so little?Journal of the American Academy of Dermatology, 2009
- Long-Term Outcomes after Repeat Doses of Antenatal CorticosteroidsNew England Journal of Medicine, 2007
- First trimester exposure to corticosteroids and oral cleftsBirth Defects Research Part A: Clinical and Molecular Teratology, 2003
- Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center’s experience update at 13 years1Transplantation, 2003
- Congenital MalformationsNew England Journal of Medicine, 1983
- Studies on Human Semen in Topical Corticosteroid-Treated and in Methotrexate-Treated PsoriaticsDermatology, 1977